Case 5:23-cv-06360-EJD Document 54-4 Filed 03/27/24 Page 1 of 3
`Case 5:23-cv-06360-EJD Document 54-4 Filed 03/27/24 Page 1of3
`
`EXHIBIT D
`
`EXHIBIT D
`
`
`
`

`

`9/29/23, 12:08 PM
`
`Bio-Rad's QX600 Droplet Digital PCR System Advancing Measurable Residual Disease Research | Bio-Rad
`Case 5:23-cv-06360-EJD Document 54-4 Filed 03/27/24 Page 2 of 3
`
` 
`
` 0
`
`Search
`
`Home > Product News > Bio-Rad's QX600 Droplet Digital PCR System Advancing Measurable Residual Disease Research
`
`Bio-Rad's QX600 Droplet Digital PCR System Advancing Measurable Residual
`Disease Research
`
`Date:
`
`2023-04-05
`
`HERCULES, Calif.—Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life
`science research and clinical diagnostic products, is accelerating measurable residual disease
`(MRD) research through more than a half dozen collaborations with institutions and companies
`leveraging its new QX600™ Droplet Digital™ PCR System. Launched late last year, it boasts six color
`detection capable of quantifying 12 targets per well, a simple user workflow, and powerful data
`analysis. Maintaining Bio-Rad's best-in-class ddPCR™ technology, this platform utilizes the same
`droplet generation and processing protocols as the QX200™ system, enabling thousands of current
`customers to easily adopt its advanced multiplexing capabilities.
`
`One such collaborator is already planning ways to apply the new QX600 ddPCR System. "The
`QX600 is an incredibly powerful instrument,” said Gary Pestano, PhD, Chief Development Officer at
`Biodesix, Inc., who also served as a beta tester. "We anticipate leveraging this tool for rare variant
`detection as a method of analyzing multiple mutations for MRD and therapeutic response testing
`for our blood-based oncology offerings. We also expect that this will drive the development of
`novel, multiplexed assays that were not possible before."
`
`The introduction of the QX600 ddPCR System expands the company's family of QX platforms,
`which currently includes the CE Marked IVDR compliant QX200 system, the FDA-cleared QXDx™
`system; and the high-throughput, fully automated QX ONE™ system.
`
`"Combining high multiplexing power with the proven sensitivity and absolute quantification of
`ddPCR technology will allow us to obtain greater volumes of high-quality clinical research data
`without burdening patients, ultimately driving precision medicine forward," said Boris Wong, MSc, a
`translational researcher at the University of Melbourne who participated in beta testing for the
`QX600 ddPCR System earlier this year.
`
`"The QX200 system has been an outstanding workhorse, cited in over 6,300 publications with
`nearly 1,000 of those focused on oncology,” said Stephen Kulisch, Vice President of Marketing for
`Bio-Rad's Digital Biology Group. “With the launch of the QX600 system, we’re excited to bring
`advanced multiplexing and unmatched sensitivity to molecular oncology investigators engaged in
`everything from biomarker discovery to clinical trials and patient monitoring of MRD."
`
`BIO-RAD, ddPCR, Droplet Digital , QXDx, QX200 and QX600 are trademarks of Bio-Rad
`Laboratories, Inc. in certain jurisdictions.
`
`About Bio-Rad 
`Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing,
`and marketing a broad range of innovative products for the life science research and clinical
`diagnostic markets. With over 70 years of focus on quality and customer service, our products
`advance the scientific discovery process and improve healthcare. Our customers are universities,
`research institutions, hospitals, biotechnology and pharmaceutical companies, as well as public
`health and commercial laboratories, including food safety and environmental quality testing
`
`1/3
`
`
`https://www.bio-rad.com/en-us/life-science-research/news/bio-rads-qx600-droplet-digital-pcr-system-advancing-measurable-residual-disease-researc…
`
`
`

`

`9/29/23, 12:08 PM
`
`Bio-Rad's QX600 Droplet Digital PCR System Advancing Measurable Residual Disease Research | Bio-Rad
`Case 5:23-cv-06360-EJD Document 54-4 Filed 03/27/24 Page 3 of 3
`facilities. Based in Hercules, California, Bio-Rad has a global network of operations with
`approximately 8,300 employees worldwide and $2.8 billion in revenues in 2022. For more
`
`information, please visit bio-rad.com.
`
`
`Forward-Looking Statements 
`This release may be deemed to contain certain forward-looking statements within the meaning of
`the Private Securities Litigation Reform Act of 1995. These forward-looking statements include,
`without limitation, statements we make regarding our products and our expectations about our
`products. Forward-looking statements generally can be identified by the use of forward-looking
`terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate,"
`"continue," or similar expressions or the negative of those terms or expressions, although not all
`forward-looking statements contain these words. Such statements involve risks and uncertainties,
`which could cause actual results to vary materially from those expressed in or indicated by the
`forward-looking statements. These risks and uncertainties include the duration and severity of the
`COVID-19 pandemic, supply chain risks, our ability to develop and market new or improved
`products, our ability to compete effectively, international legal and regulatory risks, and product
`quality and liability issues. For further information regarding our risks and uncertainties, please refer
`to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and
`Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange
`Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on
`Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements,
`which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to
`update these forward-looking statements.
`
`Media Contacts:
`Linda Healan
`CG Life
`Lhealan@cglife.com
`
`Follow Us
`
`About Bio-Rad
`
`Sustainability
`
`     
`
`Bioradiations
`
`Corporate News
`
`Contact Us
`
`Careers
`
`Investor Relations
`
`Home
`
`Cybersecurity
`
`Privacy
`
`Trademarks
`
`Web Accessibility
`
`Site Terms
`
`Terms & Conditions
`
`United States
`
`https://www.bio-rad.com/en-us/life-science-research/news/bio-rads-qx600-droplet-digital-pcr-system-advancing-measurable-residual-disease-researc… 2/3
`
`© 2023 Bio-Rad Laboratories, Inc.
`
`